Aggregation of Detergent-insoluble Tau Is Involved in Neuronal Loss but Not in Synaptic Loss*

Neurofibrillary tangles (NFTs), which consist of highly phosphorylated tau, are hallmarks of neurodegenerative diseases including Alzheimer disease (AD). In neurodegenerative diseases, neuronal dysfunction due to neuronal loss and synaptic loss accompanies NFT formation, suggesting that a process associated with NFT formation may be involved in neuronal dysfunction. To clarify the relationship between the tau aggregation process and synapse and neuronal loss, we compared two lines of mice expressing human tau with or without an aggregation-prone P301L mutation. P301L tau transgenic (Tg) mice exhibited neuronal loss and produced sarcosyl-insoluble tau in old age but did not exhibit synaptic loss and memory impairment. By contrast, wild-type tau Tg mice neither exhibited neuronal loss nor produced sarcosyl-insoluble tau but did exhibit synaptic loss and memory impairment. Moreover, P301L tau was less phosphorylated than wild-type tau, suggesting that the tau phosphorylation state is involved in synaptic loss, whereas the tau aggregation state is involved in neuronal loss. Finally, increasing concentrations of insoluble tau aggregates leads to the formation of fibrillar tau, which causes NFTs to form.

[1]  E. Mandelkow,et al.  Proline-directed Pseudo-phosphorylation at AT8 and PHF1 Epitopes Induces a Compaction of the Paperclip Folding of Tau and Generates a Pathological (MC-1) Conformation* , 2008, Journal of Biological Chemistry.

[2]  A. Takashima,et al.  GSK-3β Is Required for Memory Reconsolidation in Adult Brain , 2008, PLoS ONE.

[3]  A. Takashima,et al.  Hyperphosphorylated tau in parahippocampal cortex impairs place learning in aged mice expressing wild‐type human tau , 2007, The EMBO journal.

[4]  M. Vitek,et al.  The Tau N279K Exon 10 Splicing Mutation Recapitulates Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 Tauopathy in a Mouse Model , 2007, The Journal of Neuroscience.

[5]  Hyonchol Kim,et al.  Granular tau oligomers as intermediates of tau filaments. , 2007, Biochemistry.

[6]  B. Crain,et al.  Comparison of extent of tau pathology in patients with frontotemporal dementia with Parkinsonism linked to chromosome 17 (FTDP‐17), frontotemporal lobar degeneration with Pick bodies and early onset Alzheimer’s disease , 2006, Neuropathology and applied neurobiology.

[7]  B. Hyman,et al.  Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. , 2006, The American journal of pathology.

[8]  Ger J. A. Ramakers,et al.  Improved Long-Term Potentiation and Memory in Young Tau-P301L Transgenic Mice before Onset of Hyperphosphorylation and Tauopathy , 2006, The Journal of Neuroscience.

[9]  S. Maeda,et al.  Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer's disease , 2006, Neuroscience Research.

[10]  H. Steinhoff,et al.  Global hairpin folding of tau in solution. , 2006, Biochemistry.

[11]  J. Ávila,et al.  Characterization of a double (amyloid precursor protein-tau) transgenic: Tau phosphorylation and aggregation , 2005, Neuroscience.

[12]  K. Ashe,et al.  Age-Dependent Neurofibrillary Tangle Formation, Neuron Loss, and Memory Impairment in a Mouse Model of Human Tauopathy (P301L) , 2005, The Journal of Neuroscience.

[13]  Naoaki Saito,et al.  Transgenic mice expressing mutant (N279K) human tau show mutation dependent cognitive deficits without neurofibrillary tangle formation , 2005, FEBS letters.

[14]  Michel Goedert,et al.  Mutations causing neurodegenerative tauopathies. , 2005, Biochimica et biophysica acta.

[15]  I. Grundke‐Iqbal,et al.  Promotion of Hyperphosphorylation by Frontotemporal Dementia Tau Mutations* , 2004, Journal of Biological Chemistry.

[16]  J. Streffer,et al.  Transgenic animal models of Alzheimer's disease and related disorders: histopathology, behavior and therapy , 2004, Molecular Psychiatry.

[17]  M. Albert,et al.  Early Aβ accumulation and progressive synaptic loss, gliosis, and tangle formation in AD brain , 2004, Neurology.

[18]  T. Hashikawa,et al.  Aberrant Tau Phosphorylation by Glycogen Synthase Kinase-3β and JNK3 Induces Oligomeric Tau Fibrils in COS-7 Cells* , 2002, The Journal of Biological Chemistry.

[19]  E. Mandelkow,et al.  Mutations of Tau Protein in Frontotemporal Dementia Promote Aggregation of Paired Helical Filaments by Enhancing Local β-Structure* , 2001, The Journal of Biological Chemistry.

[20]  Akihiko Takashima,et al.  Formation of Filamentous Tau Aggregations in Transgenic Mice Expressing V337M Human Tau , 2001, Neurobiology of Disease.

[21]  Jürgen Götz,et al.  Tau and transgenic animal models , 2001, Brain Research Reviews.

[22]  H. Paudel,et al.  Neuronal Cdc2-like Protein Kinase (Cdk5/p25) Is Associated with Protein Phosphatase 1 and Phosphorylates Inhibitor-2* , 2001, The Journal of Biological Chemistry.

[23]  R. Ravid,et al.  Molecular analysis of mutant and wild-type tau deposited in the brain affected by the FTDP-17 R406W mutation. , 2001, The American journal of pathology.

[24]  E. Mandelkow,et al.  Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. , 2000, Biochemistry.

[25]  Wen-Lang Lin,et al.  Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein , 2000, Nature Genetics.

[26]  M. Goedert,et al.  Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. , 2000, Biochimica et biophysica acta.

[27]  M. Hutton Molecular genetics of chromosome 17 tauopathies , 2000, Neurobiology of Aging.

[28]  M. Hutton,et al.  Accelerated filament formation from tau protein with specific FTDP‐17 missense mutations , 1999, FEBS letters.

[29]  Richard Hollister,et al.  Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease , 1997, Annals of neurology.

[30]  P. Davies,et al.  A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Sangmook Lee,et al.  Exonic point mutations of human tau enhance its toxicity and cause characteristic changes in neuronal morphology, tau distribution and tau phosphorylation in the lamprey cellular model of tauopathy. , 2009, Journal of Alzheimer's disease : JAD.

[32]  D Patterson,et al.  Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention. , 2007, Journal of Alzheimer's disease : JAD.

[33]  Alexandra Flemming,et al.  Infectious disease: Unravelling SARS lethality , 2005, Nature Reviews Drug Discovery.